Oncology and Hematology Editors' Choice: Top Stories of 2013

Letter to Readers |
December 31, 2013

Oncology and Hematology Editors' Choice: Top Stories of 2013

  1. William J. Gradishar, MD

A perspective on the most important research from the past year

  1. William J. Gradishar, MD

This has been an exciting year for us, as we have changed our name to NEJM Journal Watch Oncology and Hematology. We remain devoted to providing clinicians with the information they need to give their patients the best care — and, as part of NEJM Group, we are now poised to do that better than ever. We are working to provide you with richer content, enhanced graphics, and a new website. Of course, our primary goal of serving you has not changed: We seek to provide you with the most current, clinically relevant information to assist you in your practice.

This year, our list of the NEJM Journal Watch Oncology and Hematology top 10 Stories covers a broad range of topics, including benign and malignant hematology and cancers of the breast, lung, prostate, and pancreas. These summaries highlight our goal of identifying the most clinically relevant manuscripts and highlighting their key points, limitations, and applications. We look forward to continuing to bring you concise summaries of the most important research in oncology and hematology during the coming year.

Our Oncology and Hematology Top Stories of 2013 are:

Ponatinib for Philadelphia Chromosome–Positive Leukemias

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Breast Cancer

Nab-Paclitaxel plus Gemcitabine Improves Survival in Pancreatic Cancer

Management of Superficial Venous Thrombosis

Smoldering Multiple Myeloma: Dousing the Fire?

Ibrutinib for Mantle-Cell Lymphoma

Curing Acute Promyelocytic Leukemia Without Chemotherapy

Dual-Maintenance Therapy for Advanced Non–Small-Cell Lung Cancer

Late Effects of Interventions for Localized Prostate Cancer

Abiraterone Effective for Chemotherapy-Naive Prostate Cancer Patients

Editor Disclosures at Time of Publication

  • Disclosures for William J. Gradishar, MD at time of publication Consultant / Advisory board Biologics, Inc.; Celgene; Myriad; Novartis Grant / research support Breast Cancer Research Fund Editorial boards Clinical Breast Cancer; Journal of Clinical Oncology; Oncology

Reader Comments (4)

KHANYISILE PHAYANE Physician, Pediatrics/Adolescent Medicine, UNIVERSITY HOSPITAL

Thank you this is very useful in my line of work!

Robert Lee Other, Pathology, Retired from Dept Path.- Univ Pittsburgh- Pgh,PA (1960-2010)

Thank you for a great chance to review "What's New & Important"

King,sonia Other Healthcare Professional, Pharmacology/Pharmacy, Quinte Healthcare Belleville Ontario Canzda

Enjoy getting the highlights each month.

aixue Physician, Oncology

i am major in chemotherapy.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.